top of page
Search

Amyloidosis (AL vs AA) for MRCP Part 1

TL;DR

Rheum: Amyloidosis (AL vs. AA) is a high-yield MRCP Part 1 topic that tests your ability to distinguish plasma cell–related AL amyloidosis from inflammation-driven AA amyloidosis. Focus on underlying causes, organ involvement (especially cardiac vs renal), and investigations such as serum electrophoresis and biopsy. Remember: AL = light chains + myeloma; AA = chronic inflammation + serum amyloid A.


Why this matters

Amyloidosis is a classic integrative topic in MRCP Part 1, bridging rheumatology, nephrology, and haematology. Questions often require you to identify the type of amyloidosis based on subtle clinical clues—particularly the underlying condition and dominant organ involvement.

Understanding AL versus AA amyloidosis can secure straightforward marks in single best answer questions and help avoid common traps. For a broader syllabus context, see the MRCP Part 1 overview.


Core sections

1. Definition and pathophysiology

Amyloidosis refers to a group of diseases characterised by extracellular deposition of misfolded protein fibrils, leading to progressive organ dysfunction.

Key pathological features:

  • Congo red staining positivity

  • Apple-green birefringence under polarised light

  • Beta-pleated sheet protein structure

2. AL vs AA Amyloidosis (High-Yield Comparison)

Feature

AL Amyloidosis

AA Amyloidosis

Protein type

Immunoglobulin light chains

Serum amyloid A protein

Cause

Plasma cell dyscrasia (e.g. multiple myeloma)

Chronic inflammation (e.g. RA, TB)

Common organs

Heart, kidneys, peripheral nerves

Kidneys, liver, spleen

Cardiac involvement

Common, severe

Rare

Key investigations

Serum/urine electrophoresis, free light chains

Raised ESR/CRP

Prognosis

Poor (especially cardiac)

Better if cause treated

3. AL Amyloidosis (Primary)

Mechanism: Deposition of monoclonal immunoglobulin light chains produced by abnormal plasma cells.

Associated conditions:

  • Multiple myeloma

  • Monoclonal gammopathy of undetermined significance (MGUS)

Clinical features:

  • Restrictive cardiomyopathy (hallmark)

  • Nephrotic syndrome

  • Peripheral/autonomic neuropathy

  • Macroglossia (highly characteristic)

  • Periorbital purpura

Investigations:

  • Serum protein electrophoresis (M protein spike)

  • Urine Bence Jones proteins

  • Serum free light chain assay

  • Bone marrow biopsy

Exam tip: Macroglossia + heart failure + proteinuria = AL amyloidosis until proven otherwise

4. AA Amyloidosis (Secondary)

Mechanism: Chronic inflammation leads to persistent elevation of serum amyloid A protein, which deposits in tissues.

Common causes:

  • Rheumatoid arthritis (most commonly tested)

  • Chronic infections (e.g. tuberculosis, bronchiectasis)

  • Inflammatory bowel disease

Clinical features:

  • Nephrotic syndrome (dominant presentation)

  • Hepatosplenomegaly

  • Less cardiac involvement

Investigations:

  • Elevated ESR and CRP

  • No monoclonal protein

  • Biopsy confirmation

Exam tip: Chronic inflammatory disease + renal dysfunction = AA amyloidosis

5. Diagnosis (Shared Principles)

Definitive diagnosis requires tissue biopsy:

  • Abdominal fat pad aspiration (least invasive)

  • Renal or rectal biopsy if needed

Staining:

  • Congo red staining

  • Polarised microscopy for birefringence

Further typing:

  • Immunohistochemistry or mass spectrometry

Authoritative reference:

6. Management Overview

AL amyloidosis:

  • Chemotherapy (e.g. bortezomib-based regimens)

  • Autologous stem cell transplantation (selected patients)

AA amyloidosis:

  • Aggressive treatment of underlying inflammatory condition

  • Biologics (e.g. anti-TNF in RA)

Further reading:

7. 10 High-Yield Exam Points

  1. AL = light chains = plasma cell disorder

  2. AA = chronic inflammation

  3. Congo red → apple-green birefringence

  4. Cardiac involvement → AL and poor prognosis

  5. Macroglossia → classic AL sign

  6. Nephrotic syndrome → common in both

  7. Serum electrophoresis abnormal in AL

  8. ESR/CRP elevated in AA

  9. Fat pad biopsy = initial diagnostic test

  10. Treat underlying disease in AA to halt progression

Medical student revising rheumatology notes for MRCP Part 1 exam preparation

Practical examples / mini-cases

MCQ Example

A 58-year-old man with long-standing rheumatoid arthritis presents with ankle swelling and proteinuria. Blood tests show elevated CRP. There is no evidence of monoclonal gammopathy.

What is the most likely diagnosis?

A. AL amyloidosisB. AA amyloidosisC. Minimal change diseaseD. Diabetic nephropathyE. Focal segmental glomerulosclerosis

Answer: B. AA amyloidosis

Explanation: Chronic inflammatory disease (RA) with nephrotic syndrome and raised inflammatory markers strongly indicates AA amyloidosis. Lack of monoclonal protein helps exclude AL.

👉 Practise more with Free MRCP MCQs or assess readiness via a Start a mock test.


Common pitfalls (5 bullets)

  • Confusing AL and AA when both present with proteinuria

  • Missing macroglossia as a key AL clue

  • Forgetting cardiac involvement is uncommon in AA

  • Assuming all amyloidosis involves monoclonal proteins

  • Ignoring chronic inflammatory diseases as triggers for AA


FAQs

1. What is the key difference between AL and AA amyloidosis?

AL is due to immunoglobulin light chains from plasma cell disorders, whereas AA results from chronic inflammation and elevated serum amyloid A protein.

2. Which organs are most commonly affected?

AL commonly affects the heart and kidneys, while AA primarily affects the kidneys and liver.

3. What is the gold standard for diagnosis?

Tissue biopsy with Congo red staining demonstrating apple-green birefringence.

4. Which type has worse prognosis?

AL amyloidosis, especially with cardiac involvement.

5. How is AA amyloidosis treated?

By controlling the underlying inflammatory disease, often with immunosuppressive or biologic therapy.


Ready to start?

Amyloidosis is a high-yield differentiation topic in MRCP Part 1. Mastering AL versus AA distinctions can secure quick, high-confidence marks.


Sources

 
 
 

Comments

bottom of page